Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2020 - 2027

Report Overview

The global biodefense market size was valued at USD 12.3 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 5.9% from 2020 to 2027. Biodefense is a set medical or military measures that are taken in response to restoring biosecurity of a country against biological toxins or infectious agents that can be used with an intent to kill or infect humans, animals, or the environment and to instigate biological warfare. Agents used for bioterrorism can be living organisms, such as bacteria, viruses, fungi, and toxins. These agents can be used deliberately to infect humans and to kill them to create social and economic turmoil. Factors such as favorable government initiatives in the U.S., growing investment from private players, increased government focus and funding towards biodefense strategies, and growing prevalence of various agents such as the Ebola Virus, Zika Virus, and Flu, are driving the market for biodefense.

The advent of technological advancement in the field of genetic engineering and biotechnology in the last decades has provided ease in modifying these fatal and naturally occurring viruses, which can be re-engineered to create more harm. Moreover, these organisms can be easily obtained which makes biodefense a crucial aspect for countries around the world. Biological agents that have been used as a carrier for bioterrorism in the past include anthrax, botulism, and chemical and nuclear agents and caused serious economic vandalism. These instances had made government construct biodefense acts, treaties, and policies to counter biological threats, reduce risks, and prepare for, respond to, and recover from bio-incidents. Since the anthrax bio-terrorism act that was carried out in 2001 through mails, The National Institute of Infectious Disease has played a vital role to develop medical products and strategies to counter bioterrorism and emerging and re-emerging infectious diseases by carrying out continuous research to diagnose, treat, and prevent them, whether deliberate or naturally occurring.

Governments of many countries have been collaborating with several international partners to support response activities and increase preparedness. For instance, an experimental single-dose Ebola vaccine manufactured by Merck [rVSV-ZEBOV-GP] has been authorized under safe use by the World Health Organization and DRC MoH. As of November 17, 2019, approximately 250,000 persons at risk for Ebola have been vaccinated. Developed economies are sending aids to countries with weak medical infra and low research capabilities many companies like Bavarian Nordic and Ology Bioservices are carrying out researches on Ebola and Zika virus. The introduction of the Project BioShield Act was a strategic decision to increase funding for procuring, developing, and utilizing medical countermeasures against biological, chemical, radiological, and nuclear (CBRN) warfare agents. These above-mentioned factors and the rising risk of prevalence of the infectious disease are expected to boost the growth of the market for biodefense.

Product Insights

The anthrax segment dominated the market for biodefense and held the largest revenue share of 29.6% in 2019. The segment is expected to reciprocate a significant CAGR over the forecast period. Based on the product, the market for biodefense is segmented into anthrax, smallpox, botulism, radiation/ nuclear, and others. Bacillus anthracis is a gram-positive bacteria that cause anthrax and is one of the most likely used weapons for bioterrorism. These spores are mostly preferred as they can be easily released into the environment by placing them in food, water, powder, and sprays. They can last for a long time in the environment and are easily found in nature (soil, plants, or water). According to NCBI, Anthrax bacteria is categorized as tier 1 biological agent as it can be transmitted easily from one person to another and possess the potential for major public health impact. Countermeasures against anthrax are one of the areas that have received major vaccine development funding by Project BioShield. Many companies have their vaccine for anthrax in clinical trials.

The other product segment is expected to reciprocate the highest CAGR over the forecast period in the market for biodefense. The others segment includes viruses like viral hemorrhagic fever, brucellosis, cholera, influenza, plague, food poisoning, tularemia, Zika, and Ebola. The National Institute of Allergy and Infectious Diseases (NIAID) has a Vaccine Research Centre (VRC), which is working on VHF vaccines since 2003, especially against Ebola and Marburg viruses. The University of Texas at San Antonio (UTSA) has been awarded a contract from the U.S. Department of Defense (DoD) to develop a vaccine against tularemia. Tularemia being highly infectious and at times fatal in nature has developed as a bioweapon. Recently many countries have witnessed a rise in Zika and Ebola virus infections and therefore many companies are competing to develop vaccines. MVA-BN Filo, manufactured by Bavarian Nordic, is a vaccine against the most common causes of viral hemorrhagic fever; Ebola and Marburg virus. The vaccine is currently under phase 3 clinical trials and the company has collaborated with the U.S. NIAID for the same.

Regional Insights

North America dominated the biodefense market and accounted for the largest revenue share of 87.8% in 2019. The region is expected to showcase a significant CAGR over the forecast period. This is attributed to the presence of high federal funding, technological advancements, and growing awareness among the population. The presence of major players in this region is also a favorable prospect for the market. Based on Federal Research and Development (R&D) Funding, in the fiscal year 2017, out of the total funding that was received by eight federal agencies, 96.3% of it was received by the Department of Defense (39.3%) and the Department of Health and Human Services (27.3%). This percentage of funding to DoD is proposed to increase to 48.4% in 2019. National Biodefense Strategy is aligned with the 2018 National Security Strategy of the United States. The strategy is to detect and contain biothreats at their source, support and promote biomedical innovation, and improve emergency response in case of biological outbreaks. Such government initiatives are driving the market for biodefense in the region.

In APAC, the market for biodefense is expected to witness the highest CAGR of 10.6% over the forecast period due to surging investments in R&D. In addition to this, the growing significance of biodefense and the rising threat of harmful biological materials that engender emergencies are also driving the market for biodefense in the region. Australia and Japan are two of the most mature markets for biodefense in the region as there are well-established vaccine production facilities in these countries. Along with that, the presence of sophisticated healthcare infrastructure in the country contributes to its market position. Countries like India and China are rigorously expanding their R&D capabilities to cater to biological threats in the future. China is the second country after the U.S. to spend the largest percentage of its GDP on R&D. These are the factors that are expected to boost the market for biodefense in the region.

Key Companies & Market Share Insights

The market for biodefense is highly competitive in nature. One of the key factors driving competitiveness among market players is the rapid adoption of advanced technology to develop vaccines and drugs. Key players are rapidly opting for strategic collaborations with the governments to receive bulk orders and to increase sales volume in emerging and economically favorable regions. Many companies are partnering with each other to develop drugs to introduce their products faster in the market for biodefense. For instance, in March 2019, Ichor Medical Systems, Inc. which is a privately-held biotech company announced that it had entered into a collaboration and research license agreement with AstraZeneca for the development and clinical assessment of plasmid DNA constructs (recombinant monoclonal antibody). Under the terms of the agreement, Ichor will receive upfront and annual payments along with developmental milestones. Some of the prominent players in the biodefense market include:

• XOMA corporation

• Altimmune Inc.

• Emergent Biosolutions Inc.

• Dynavax Technologies Corporation.

• SIGA Technologies.

• Elusys Therapeutics Inc.

• Ichor Medical Systems.

• Dynport Vaccine Company.

• ClevelandBiolabs.

• Bavarian Nordic.

• Ology Bioservices.

• Alnylam Pharmaceuticals Inc

Biodefense Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global biodefense market report on the basis of product and region:

• Product Outlook (Revenue, USD Million, 2016 - 2027)

  • Anthrax

  • Smallpox

  • Botulism

  • Radiation/nuclear

  • Others

• Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • India

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa